Literature DB >> 1658648

Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance.

P J Dyck1, P A Low, A J Windebank, S S Jaradeh, S Gosselin, P Bourque, B E Smith, K M Kratz, J L Karnes, B A Evans.   

Abstract

BACKGROUND: Polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS) has been treated with plasma exchange, intravenous immune globulin, and chemotherapy, but the effectiveness of these treatments remains uncertain.
METHODS: We randomly assigned 39 patients with stable or worsening neuropathy and MGUS of the IgG, IgA, or IgM type to receive either plasma exchange twice weekly for three weeks or sham plasma exchange, in a double-blind trial. The patients who initially underwent sham plasma exchange subsequently underwent plasma exchange in an open trial.
RESULTS: In the double-blind trial, the average neuropathy disability score improved by 2 points from base line (from 62.5 to 60.5) in the sham-exchange group and by 12 points (from 58.3 to 46.3) in the plasma-exchange group (P = 0.06). A similar difference was observed in the weakness score, a component of the neuropathy disability score (improvement, 1 and 10 points, respectively; P = 0.07). After treatment the summed compound muscle action potentials of motor nerves were 1.2 mV lower (worse) than at base line in the sham-exchange group and 0.4 mV higher (better) in the plasma-exchange group (P = 0.07). The greater degree of improvement with plasma exchange was equal in magnitude to or greater than the difference between not being able to walk on the heels or toes and being able to perform these activities. Changes in the vibratory detection threshold, summed motor-nerve conduction velocity, and sensory-nerve action potentials did not differ significantly between the treatment groups. In the open trial, in which patients who initially underwent sham exchange were treated with plasma exchange, the neuropathy disability score (P = 0.04), weakness score (P = 0.07), and summed compound muscle action potentials (P = 0.07) improved more with plasma exchange than they had with sham exchange. In both the double-blind and the open trial, those with IgG or IgA gammopathy had a better response to plasma exchange than those with IgM gammopathy.
CONCLUSIONS: Plasma exchange appears to be efficacious in neuropathy associated with MGUS, especially of the IgG or IgA type.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658648     DOI: 10.1056/NEJM199111213252105

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  39 in total

Review 1.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group.

Authors:  X Mariette; C Chastang; P Clavelou; J P Louboutin; J M Leger; J C Brouet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

4.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

5.  Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.

Authors:  H C Wilson; M P Lunn; S Schey; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

Review 6.  Inflammatory neuropathies.

Authors:  Hannah R Briemberg; Anthony A Amato
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

Review 7.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

Review 8.  Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

Authors:  Anne Louise Oaklander; Michael Pt Lunn; Richard Ac Hughes; Ivo N van Schaik; Chris Frost; Colin H Chalk
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

Review 9.  Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Authors:  Hafsa M Chaudhry; Michelle L Mauermann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

Review 10.  Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy.

Authors:  J M Leger; A B Younes-Chennoufi; B Chassande; G Davila; P Bouche; N Baumann; P Brunet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.